Thoraxcenter, Erasmus Medical Centre, 's-Gravendijkwal 230, 3015 GE, Rotterdam, The Netherlands,
Neth Heart J. 2015 Mar;23(3):161-5. doi: 10.1007/s12471-015-0651-3.
Percutaneous coronary interventions (PCI) have become a reliable revascularisation option to treat ischaemic coronary artery disease. Drug-eluting stents (DES) are widely used as first choice devices in many procedures due to their established good medium to long term outcomes. These permanent implants, however, do not have any residual function after vascular healing following the PCI. Beyond this initial healing period, metallic stents may induce new problems, resulting in an average rate of 2 % reinterventions per year. To eliminate this potential late limitation of permanent metallic DES, bioresorbable coronary stents or 'vascular scaffolds' (BVS) have been developed. In a parallel publication in this journal, an overview of the current clinical performance of these scaffolds is presented. As these scaffolds are currently CE marked and commercially available in many countries and as clinical evidence is still limited, recommendations for their general usage are needed to allow successful clinical introduction.
经皮冠状动脉介入治疗（PCI）已成为治疗缺血性冠状动脉疾病的一种可靠的血运重建选择。由于其确立的良好的中至长期效果，药物洗脱支架（DES）在许多介入治疗中被广泛用作首选器械。然而，这些永久性植入物在 PCI 后血管愈合后没有任何残留功能。在这个初始愈合期之后，金属支架可能会引发新的问题，导致每年平均有 2%的患者需要再次介入治疗。为了消除永久性金属 DES 的这种潜在的晚期局限性，生物可吸收冠状动脉支架或“血管支架”（BVS）已经被开发出来。在本杂志的一篇平行文章中，对这些支架目前的临床性能进行了概述。由于这些支架目前已经在 CE 标志，并在许多国家和商业上可用，由于临床证据仍然有限，需要对其一般用途提出建议，以允许成功的临床引入。
